Why is Revolution Medicines stock surging today?

Revolution Medicines (RVMD) reported $198M in first-month sales for RASONQUE, with inventory levels managed at two weeks. Prescriptions were split 40% academic and 60% community. The company expects payer coverage to evolve, with reimbursement currently strong. RASonate 312 trial is ongoing, and the company is exploring broader colorectal cancer opportunities. Management declined to comment on October trends, citing early launch stage.

Revolution Medicines (RVMD) reported $198M in Q3 2026 revenue from its newly approved drug, RAZONQ, for metastatic pancreatic cancer. The FDA approved the drug in August, and the NCCN guidelines expanded its recommended use. The company is preparing for international expansion and has received positive opinions from the EMA. RAZONQ is also being studied for non-small cell lung cancer.

Revolution Medicines (RVMD) reported Q3 earnings, highlighting RASONQUE's reimbursement progress, regulatory updates, and pipeline advancements. RASONQUE is included in NCCN guidelines for pancreatic cancer. The company expects European and potential Japanese launches. Q3 revenue included initial stocking, with R&D expenses rising to $417.1M. RVMD ended the quarter with $3.7B in cash. The company reiterated 2026 operating expense guidance and anticipates higher 2027 expenses.

Revolution Medicines (RVMD) reiterated its 2026 GAAP operating expense guidance of $2.1B-$2.2B following the FDA approval of RASONQUE, which is now available by prescription in the US. The company reported a transformational Q3 2026, according to its CEO, President, and Chairman.

Revolution Medicines, Inc. (RVMD) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Revolution Medicines Reports Third Quarter 2026 Financial Results and Update on Corporate Progress · Received U.S. FDA approval and launched RASONQUE® (daraxonrasib) for adult patients with metastatic pancreatic cancer who have received at least one prior systemic th

Revolution Medicines reported $198M in net product revenue for its pancreatic cancer drug RASONQUE in Q3 2026, following U.S. FDA approval and launch. The company also received a positive CHMP opinion for EU approval. RASONQUE is for metastatic pancreatic cancer patients. Revolution Medicines plans to scale global commercialization and advance clinical trials.